INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
Rhea-AI Summary
INVO Fertility (Nasdaq: IVF) closed its acquisition of Family Beginnings, a Midwest fertility clinic, on Feb 19, 2026 for a $760,000 combined purchase price paid in cash and preferred stock. Family Beginnings reported ~$1.0M revenue and ~$0.2M net income for the nine months ended Sept 30, 2025, representing about 18% of INVO's clinic revenue for that period.
The clinic’s medical leadership and care teams remain in place under a multi-year agreement with James Donahue, M.D., and INVO intends to provide operational support and technology investment to expand patient access.
Positive
- Revenue ~ $1.0M for nine months ended Sept 30, 2025
- Net income ~ $0.2M for nine months ended Sept 30, 2025
- Acquisition represents ~18% of INVO clinic revenue for same period
- Purchase closed for $760,000 in cash and preferred stock consideration
- Clinic medical leadership retained under a multi-year agreement
Negative
- Transaction involved acquisition of non-clinical assets, limiting direct asset control
- Consideration included preferred stock, which may have shareholder implications
News Market Reaction – IVF
On the day this news was published, IVF declined 4.18%, reflecting a moderate negative market reaction. Argus tracked a peak move of +23.8% during that session. Argus tracked a trough of -16.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $304K from the company's valuation, bringing the market cap to $7M at that time. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows one peer, BBLG, up 3.77% with no news, while sector peers like VERO, TIVC, and NUWE show mixed single-digit moves. This points to stock-specific dynamics rather than a coordinated sector move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Definitive agreement | Positive | -9.8% | Signed definitive purchase agreement for Family Beginnings with detailed cash and stock terms. |
| Nov 28 | Acquisition intent | Positive | +11.0% | Announced intent to acquire Family Beginnings as part of nationwide clinic expansion. |
Prior acquisition-related announcements for Family Beginnings produced mixed reactions: one strong gain and one notable decline, suggesting inconsistent trading responses to this theme.
Over the past few months, INVO Fertility has advanced a clinic-acquisition strategy focused on Family Beginnings. On Nov 28, 2025, it announced its intent to acquire the clinic, followed by a definitive purchase agreement on Dec 17, 2025 detailing cash and preferred stock consideration. Today’s closing announcement completes that progression, adding an established Indiana fertility center that reported $1M in nine‑month 2025 revenue and aligns with INVO’s broader clinic network expansion.
Historical Comparison
In the past six months, INVO issued two acquisition headlines on Family Beginnings with an average move of 0.61%, suggesting historically modest price reactions despite strategic importance.
Acquisition trajectory shows clear progression: initial intent to acquire Family Beginnings, execution of a definitive purchase agreement, and now transaction closing with existing leadership retained.
Market Pulse Summary
This announcement finalizes INVO’s acquisition of Family Beginnings, an Indiana fertility clinic that produced $1M in revenue and $0.2M net income over nine months, about 18% of INVO’s clinic revenue for that period. It advances a documented strategy to grow via clinic acquisitions while keeping existing medical leadership in place. Investors may watch how volumes, profitability, and integration progress at this site and how future deals are financed within the current capital structure.
Key Terms
in vitro fertilization medical
intravaginal culture medical
intrauterine insemination medical
AI-generated analysis. Not financial advice.
Strategic Transaction Advances Company’s Growth
SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest.
The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025.
Founded more than a decade ago, Family Beginnings has built a strong reputation for delivering comprehensive fertility services with a highly personalized, patient-first approach. The clinic offers a full suite of reproductive services, including in vitro fertilization, intravaginal culture (as an early adopter of the Company’s INVOcell solution), ovulation induction, intrauterine insemination, fertility preservation, and diagnostic testing, supported by an experienced clinical and embryology team. James Donahue, M.D., Family Beginnings REI and lab director, was recognized again as a 2026 Castle Connolly Top Doctor, placing him among the top
Family Beginnings is known for its continuity of care, close physician-patient relationships, and commitment to guiding patients through what is often a complex and emotional journey. These attributes align closely with INVO Fertility’s mission to expand access to high-quality, compassionate fertility care while maintaining a personalized treatment experience.
Importantly for patients, the clinic’s existing medical leadership and care teams will remain in place, ensuring continuity of care while benefiting from INVO’s broader clinical resources, operational support, and ongoing investment in advanced technologies and best practices.
Family Beginnings generated revenue of approximately
The closing of this acquisition marks an important milestone in INVO’s ongoing strategy to expand its network of fertility care centers and broaden patient access to advanced reproductive care. Under the terms of the transaction, INVO acquired the non-clinical assets of Family Beginnings for a combined purchase price of
“We are thrilled to complete the acquisition of Family Beginnings,” said Steve Shum, CEO of INVO Fertility. “This transaction not only expands our geographic footprint and enhances our portfolio of clinics, but it also advances our mission of increasing access to high-quality, patient-centered fertility care. Family Beginnings has a long-standing reputation for excellence and compassionate care, and we look forward to building on that legacy with Dr. Donahue and growing the clinic from its current operating levels.”
The closing of the Family Beginnings acquisition follows a period of meaningful progress for INVO Fertility, as highlighted in the Company’s recent shareholder letter, which underscores the clear strategic outlook centered on growth through both organic initiatives and targeted clinic acquisitions, as well as the Company enjoying its strongest fundamental position in several years.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding the Company’s ability to satisfy closing conditions for the offering, our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
What did INVO Fertility (IVF) acquire from Family Beginnings on Feb 19, 2026?
How large was Family Beginnings’ revenue contribution to INVO (IVF) in 2025?
What was the purchase price and payment structure for the IVF acquisition of Family Beginnings?
Will Dr. James Donahue continue to run Family Beginnings after the IVF acquisition?
How does the Family Beginnings acquisition affect INVO Fertility’s (IVF) growth strategy?
Does the Family Beginnings deal change clinical care at the clinic after INVO’s (IVF) acquisition?
